Cell and gene therapies have come a long way in the past 20 years. And more recent advances and successes with CRISPR and CAR-T technologies have left the field of opportunity wide open for treatments that can potentially move the needle, particularly for patients with oncologic or rare diseases. But with great advancements come significant challenges.
Pete Robinson, Vice President, Medical and Scientific Strategy and Head of the Cell & Gene Therapy Consortium and James Barwick-Silk, Director, Scientific Strategy, Cell & Gene Therapy at Syneos Health discuss the latest exciting developments, as well as hurdles the biopharmaceutical industry must overcome – from R&D, to manufacturing, to access and reimbursement – in order to successfully bring these therapies to market.
For more from our experts in rare disease, be sure to check out:
Innovation Perspectives in Rare Disease Drug Development
サイネオス・ヘルスのポッドキャスト：Mental Health in Rare Disease
サイネオス・ヘルスのポッドキャスト：Epilepsy, the Central Nervous System and Rare Disease
Prioritizing Mental Health Services for Those Living With Rare Disease
Rare Disease Drug Development: Clinical, Scientific, Patient, and Caregiver Perspectives
